Upstream Bio shows resilient revenue growth (83% YoY) but is flagged for exit given a quality score below the engine's minimum floor, extreme cash burn, multiple value-trap signals, and elevated short interest against a confirmed technical downtrend.
Thesis pillars
- Value Trap Signal Cluster→Stable
- Revenue Growth Momentum→Stable
- Cash Burn Runway Risk→Stable
- +2 more pillars — see the Why tab for full reasoning
Upstream Bio, Inc. (UPB) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend.
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody antagonist of the TSLP receptor, for inflammatory respiratory diseases including severe asthma, chronic rhinosinusitis with nasal polyps, and COPD. The company is pre-revenue,... Read more
Sell if holding. Engine safety override at $7.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 95. Score 5.7/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Upstream Bio, Inc.
About Upstream Bio, Inc.
Upstream Bio's entire clinical pipeline rests on verekitug, a monoclonal antibody targeting the TSLP receptor, which posted positive Phase 2 results in chronic rhinosinusitis with nasal polyps in September 2025 and in severe asthma in February 2026, with Phase 3 dosing planned for both indications in the first quarter of 2027. The company held $341.5 million in cash and short-term investments at December 31, 2025, expected to fund operations through 2027, and has generated no product revenue since its 2021 founding.
Upstream Bio has no approved products or product revenue; it finances development through cash on hand and its October 2024 initial public offering, having reported net losses of $143.4 million in 2025 and an accumulated deficit of $334.2 million. Verekitug originated at Astellas Pharma, which discovered the compound, ran preclinical studies, and sold the asset to Upstream Bio in October 2021; the company's development plan relies in part on the accuracy of Astellas's earlier preclinical data. Across five completed and ongoing trials, verekitug has been dosed in approximately 500 participants, and the company initiated a Phase 2 COPD trial in July 2025. The company positions verekitug against tezepelumab (marketed as Tezspire by Amgen and AstraZeneca), citing Phase 1b data showing verekitug is approximately 300-fold more potent and supports dosing intervals of up to 24 weeks versus tezepelumab's four-week interval.
Show full overview
Upstream Bio's valuation case is a single-asset bet: the 10-K states that verekitug is currently the company's only product candidate and that its business depends entirely on successfully developing, approving, and commercializing it in one or more of the three target indications. Unlike biotechs with a broader pipeline that can absorb a lead-candidate setback, Upstream Bio has no second program to fall back on if upcoming Phase 3 trials fail to replicate the positive Phase 2 signal, if the FDA requires additional studies, or if Astellas's earlier preclinical data — which the company relies on but did not generate itself — proves inaccurate or incomplete.
See also: Healthcare · Biotechnology
From Upstream Bio, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineverekitug10-K Item 1A: 'Verekitug is currently our only product candidate.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 95. Prior stop was $7.42. Score 5.7/10, moderate confidence.
Take-profit target: $7.84 (-1.8% upside). Prior stop was $7.42. Stop-loss: $7.42.
Concentration risk — Pipeline: verekitug; DATA_ISSUE: analyst_target_implausible (raw $38.25 vs price $7.98 — ratio 4.8×). Rejected, falling back to technical TP.; Quality below floor (3.5 < 4.0).
Upstream Bio, Inc. trades at a P/E of N/A (forward -2.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
13 analysts cover UPB with a consensus score of 3.9/5. Average price target: $38.
What does Upstream Bio, Inc. do?Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody antagonist of the...
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody antagonist of the TSLP receptor, for inflammatory respiratory diseases including severe asthma, chronic rhinosinusitis with nasal polyps, and COPD. The company is pre-revenue, funding development through its October 2024 IPO and existing cash, and reported net losses of $143.4 million in 2025 and an accumulated deficit of $334.2 million as of December 31, 2025.